View in EDS

TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity.

Saved in:
Bibliographic Details
Title: TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity.
Authors: Tani T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Mathsyaraja H; Gilead Sciences, Foster City, California., Campisi M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Li ZH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Haratani K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Fahey CG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Ota K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Mahadevan NR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Shi Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Saito S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Mizuno K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Thai TC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Sasaki N; Department of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan., Homme M; Department of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan., Yusuf CFB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Kashishian A; Gilead Sciences, Foster City, California., Panchal J; Gilead Sciences, Foster City, California., Wang M; Gilead Sciences, Foster City, California., Wolf BJ; Gilead Sciences, Foster City, California., Barbie TU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Paweletz CP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Gokhale PC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Liu D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Uppaluri R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Kitajima S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan., Cain J; Gilead Sciences, Foster City, California., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Source: Cancer discovery [Cancer Discov] 2024 May 01; Vol. 14 (5), pp. 752-765.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2159-8290
DOI:10.1158/2159-8290.CD-23-0700